Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours

Neuroradiology

Volumn 48, Issue 10, 2006, Pages 703-713

  Jenkinson, Michael D ^a,b   Smith, Trevor S ^a   Joyce, Kathy A ^c   Fildes, Diane ^c   Broome, John ^a   Plessis, Daniel G ^b   Haylock, Brian ^d   Husband, David J ^d   Warnke, Peter C ^e   Walker, Carol ^c  

^a WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

^d CLATTERBRIDGE HOSPITAL   (United Kingdom)

^e LEIBNIZ INSTITUTE FOR NEUROBIOLOGY   (Germany)

Author keywords

Chemosensitivity; Oligodendroglial tumour; Outcome; rCBV

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM PENTETATE MEGLUMINE; LOMUSTINE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; PROCARBAZINE; PROTEIN P53; VINCRISTINE;

ADULT; AGED; ALLELIC IMBALANCE; ARTICLE; ASTROCYTOMA; BRAIN BLOOD VOLUME; CALCULATION; CANCER COMBINATION CHEMOTHERAPY; CHEMOSENSITIVITY; CHROMOSOME 10P; CHROMOSOME 17P; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME LOSS; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; EXON; GENE MUTATION; GENOTYPE; HISTOLOGY; HUMAN; HUMAN TISSUE; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVER VARIATION; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE; STUDENT T TEST; TREATMENT OUTCOME; TUMOR CLASSIFICATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BLOOD VOLUME; BRAIN NEOPLASMS; GENOTYPE; HUMANS; LOSS OF HETEROZYGOSITY; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; OLIGODENDROGLIOMA; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33749337570     PISSN: 00283940     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00234-006-0122-z     Document Type: Article

References (37)

1. Buckner JC, Gesme D Jr, O'Fallon JR et al (2003) Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: Efficacy and associations with chromosomal abnormalities. J Clin Oncol 21:251-255
2. Cairncross JG, Ueki K, Zlatescu MC et al (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473-1479
3. Ino Y, Betensky RA, Zlatescu MC et al (2001) Molecular subtypes of anaplastic oligodendroglioma: Implications for patient management at diagnosis. Clin Cancer Res 7:839-845
4. Smith JS, Perry A, Borell TJ, et al (2000) Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18:636-645
5. van den Bent MJ (2004) Advances in the biology and treatment of oligodendrogliomas. Curr Opin Neurol 17:675-680
6. Sasaki H, Zlatescu MC, Betensky RA et al (2002) Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade "oligodendroglioma". J Neuropathol Exp Neurol 61:58-63
7. Walker C, Smith TS, Haylock B et al (2006) Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors. Neurology 66:1661-1667
8. Cha S, Tihan T, Crawford F et al (2005) Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol 26:266-273
9. Keston P, Murray AD, Jackson A (2003) Cerebral perfusion imaging using contrast-enhanced MRI. Clin Radiol 58:505-513
10. Cha S, Knopp EA, Johnson G et al (2002) Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. Radiology 223:11-29
11. Law M, Oh S, Babb JS et al (2006) Low-grade gliomas: Dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging-prediction of patient clinical response. Radiology 238:658-667
12. Warnke PC, Berlis A, Ostertag C (1998) Physiological characterization of malignant oligodendrogliomas responding to PCV chemotherapy. J Neurosurg 88:399A
13. Jager HR, Waldman AD, Benton C, Fox N, Rees J (2005) Differential chemosensitivity of tumor components in a malignant oligodendroglioma: assessment with diffusion-weighted, perfusion-weighted, and serial volumetric MR imaging. AJNR Am J Neuroradiol 26:274-278
14. Godfraind C, Rousseau E, Ruchoux MM, Scaravilli F, Vikkula M (2003) Tumour necrosis and microvascular proliferation are associated with 9p deletion and CDKN2A alterations in 1p/19q-deleted oligodendrogliomas. Neuropathol Appl Neurobiol 29:462-471
15. Jenkinson MD, Smith TS, Joyce K et al (2005) MRS of oligodendroglial tumors: Correlation with histopathology and genetic subtypes. Neurology 64:2085-2089
16. Walker C, du Plessis DG, Fildes D et al (2004) Correlation of molecular genetics with molecular and morphological imaging in gliomas with an oligodendroglial component. Clin Cancer Res 10:7182-7191
17. Walker C, du Plessis DG, Joyce KA et al (2005) Molecular pathology and clinical characteristics of oligodendroglial neoplasms. Ann Neurol 57:855-865
18. Walker C, Haylock B, Husband D et al (2006) Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors. Neurology 66:1661-1667
19. Kleihues P, Cavanee W (eds) (2000) Pathology and genetics of tumours of the nervous system. IARC Press, Lyon
20. Wetzel SG, Cha S, Johnson G et al (2002) Relative cerebral blood volume measurements in intracranial mass lesions: Interobserver and intraobserver reproducibility study. Radiology 224:797-803
21. Warmuth C, Gunther M, Zimmer C (2003) Quantification of blood flow in brain tumors: Comparison of arterial spin labeling and dynamic susceptibility-weighted contrast-enhanced MR imaging. Radiology 228:523-532
22. Levin VA, Edwards MS, Wright DC et al (1980) Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep 64:237-244
23. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280
24. Bland JM, Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1:307-310
25. Law M, Yang S, Wang H et al (2003) Glioma grading: Sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 24:1989-1998
26. Maia AC Jr, Malheiros SM da Rocha AJ, et al (2005) MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. AJNR Am J Neuroradiol 26:777-783
27. Hakyemez B, Erdogan C, Ercan I et al (2005) High-grade and low-grade gliomas: Differentiation by using perfusion MR imaging. Clin Radiol 60:493-502
28. Lev MH, Ozsunar Y, Henson JW et al (2004) Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: Confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol 25:214-221
29. Roberts HC, Roberts TP, Bollen AW et al (2001) Correlation of microvascular permeability derived from dynamic contrast-enhanced MR imaging with histologic grade and tumor labeling index: A study in human brain tumors. Acad Radiol 8:384-391
30. Aronen HJ, Gazit IE, Louis DN et al (1994) Cerebral blood volume maps of gliomas: Comparison with tumor grade and histologic findings. Radiology 191:41-51
31. Aronen HJ, Pardo FS, Kennedy DN et al (2000) High microvascular blood volume is associated with high glucose uptake and tumor angiogenesis in human gliomas. Clin Cancer Res 6:2189-2200
32. Sugahara T, Korogi Y, Kochi M et al (1998) Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. AJR Am J Roentgenol 171:1479-1486
33. Xu M, See SJ, Ng WH et al (2005) Comparison of magnetic resonance spectroscopy and perfusion-weighted imaging in presurgical grading of oligodendroglial tumors. Neurosurgery 56:919-926; discussion 919-926
34. Birner P, Gatterbauer B, Oberhuber G et al (2001) Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: Its impact on prognosis and on neoangiogenesis. Cancer 92:165-171
35. Christov C, Adle-Biassette H, Le Guerinel C, Natchev S, Gherardi RK (1998) Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the vasculature of oligodendrogliomas. Neuropathol Appl Neurobiol 24:29-35
36. Schiffer D, Bosone I, Dutto A, Di Vito N, Chio A (1999) The prognostic role of vessel productive changes and vessel density in oligodendroglioma. J Neurooncol 44:99-107
37. Vaquero J, Zurita M, Morales C, Coca S (2002) Prognostic significance of tumor-enhancement and angiogenesis in oligodendroglioma. Acta Neurol Scand 106:19-23